INTRODUCTION
Normally the cornea in human eye is crystalline clear membrane present in the anterior most portion of the eyeball. Regarding the various functions of the cornea in human eye it provides protection, clear vision, refractive media of the visual system and maintains itself as an immune privileged site. Various Ocular insults that include microbial keratitis, immunological conditions, trauma, chemical injury and contact lens wear may cause neovascularization (NV) in cornea. 1 Neovascularization is mostly associated with an inflammation and always indicate a state of disease. However corneal neovascularization is useful in corneal wound healing after injury or in elimination of infection, but it cause reduction in corneal transparency. Decreased corneal transparency can cause visual acuity deterioration. Similarly Corneal Neovascularization can cause Graft rejection reaction after keratoplasty. 2 keratoplasty (corneal transplantation) is usually performed to restore vision. Indications of Keratoplasty includes therapeutic reasons, in corneal ulcers not responding to medical therapy or to improve the structural integrity of cornea secondary to diseases that induced corneal stromal thinning. Various Factors that can affect the success rate of corneal transplantation depend on presence of corneal neovascularization, some pre-exciting ocular diseases like glaucoma or dry eyes, type of keratoplasty and effective management of postoperative complications.
According to various studies, neovascularization in cornea occurs when there imbalance between angiogenic and anti-angiogenic factors and Increased in blood level of angiogenic factors will induced neovascularization in cornea. One of the most common mediators of angiogenesis in cornea is Vascular endothelial growth factor (VEGF) that is up regulated during neovascularization. Different studies proved that Vascular endothelial growth factor (VEGF) is a potent stimulator of endothelial cell growth in vitro and neovascularization in vivo. The Vascular endothelial growth factor can cause neovascularization in other different clinical diseases such as tumors, proliferative diabetic retinopathy, exudative age-related macular degeneration. The different types of anti-VEGF agents now are used to prevent neovascular eye diseases. 4 These different Anti-VEGF inhibitors are Lucentis, Macugen and bevacizumab/Avastin are used in case of ocular neovascularization. 5 Regarding Avastin, it is a recombinant humanized monoclonal immunoglobulin antibody specifically directed against human vascular endothelial growth factor (VEGF). While the mechanism of action of Avastin, it binds to soluble VEGF molecules that leads to prevention of its receptor binding capacity that finally inhibits endothelial cell proliferation and vessel formation. 6 Regarding the use of subconjuctival bevacizumab in terms of regression of corneal neovascularization is controversial in literature. So, this study is conducted to evaluate the efficacy of subconjunctival bevacizumab in regressing the corneal neovascularization to reduce the risk of corneal graft rejection following keratoplasty as well as making transparent cornea after keratoplasty.
OBJECTIVE
The main purpose of this study was to: To find out the efficacy of subconjuctival injection of Avastin in patients that developed neovascularization in cornea after Keratoplasty.
MATERIAL AND METHODS Study Design:
Descriptive case series.
Settings
Department of Ophthalmology Allied Hospital, Faisalabad and Independent University Hospital, Faisalabad.
Study Duration:
The duration of study was 11-02-2015 to 11-07-2015.
Sample Size
The total number of patients in this study was 86.
Sampling Technique
Non Probability, Consecutive sampling.
SAMPLE SELECTION

Inclusion Criteria
Patients having age range of 35-65 years of both gender and Patients with corneal neovascularization after Keratoplasty were included in this study.
Exclusion Criteria
Patients having history of use of contact lens, a thromboembolic event, corticosteroid, antithrombotic drugs or aspirin, uncontrolled hypertension or diabetes mellitus were not included in study.
Data Collection Methods
After the approval of hospital ethical committee, patients coming through the OPD of the eye department who fulfilled the inclusion criteria were enrolled and informed consent was taken from all patients.
In Keratoplasty diseased cornea is replaced by healthy donor corneal tissue. Keratoplasty may be full thickness or partial thickness. The fullthickness Keratoplasty is the most commonly performed method as compared to partial thickness Keratoplasty in most of cases. In fullthickness Keratoplasty topical, local, or general anesthesia can be used depending on Surgeon preference. In this study all patients underwent full thickness Keratoplasty under local anesthesia. Subconjuctival avastin of dose of 2.5 mg/0.1 www.theprofesional.com SUBCONJUNCTIVAL INJECTION 298 3 ml per affected quadrant was injected at the area of new vessels formation in those patients that developed corneal neovascularization after Keratoplasty. For assessing the regression of corneal neovascularization and improved corneal transparency after 6 months of treatment complete slit lamp examination with photo documentation was performed. During the Postoperative time all patients were advised topical antibiotics, Lubicants and steroids eye drops. Regular follow up first after two weeks, then on monthly basis for six months after injection was done of all patients and all the information was collected on Performa. Data analysis was performed by SPSS version 16. Mean+Standard deviation was calculated for all quantitative variables. P-value < 0.05 was taken as significant.
RESULTS
A total of 86 cases fulfilling the inclusion/ exclusion criteria were enrolled in this study. The subconjuctival injection of Avastin was used in these patients that developed corneal neovascularization after keratoplasty.
Patients were distributed according to age showing that 75.58% (n=65) were between 35-50 years while 24.42% (n=21) were between 51-65 years of age, mean+sd was calculated as 45.63+7.10 years. (Table-I) 72.09% (n=62) were male and 27.91% (n=24) were females according to Gender distribution the patients. (Table-II) In these patients 82.56% (n=71) frequency of efficacy of subconjuctival injection of avastin was recorded in patients that developed corneal neovascularization after keratoplasty while no efficacy was recorded in 17.44% (n=15) cases. (Table-III However, In another study regression of corneal neovascularization was observed in 66.7% (8/12 patients). 8 So findings this study not match with our study.
Koenig et al conducted study of bevacizumab on 30 eyes of 27 patients who were not improving by commonly used anti-inflammatory drugs. They reported that a 61% reduction observed in area of corneal neovascularization and reduction in vessel diameter was 24% in these patients. 9 Another study recommended that maximal effects of bevacizumab for reduction of corneal neovascularization observed when this drug was used early in the course of disease. 10 Other human study conducted by Kim SW, Ha BJ, Kim EK also reported the efficacy of bevacizumab in reducing abnormal corneal vessels. 11 Dastjerdi et al conducted a study in 2009 on 10 eyes from 10 patients. .After the treatment with bevacizumab these patients presented with clinically stable neovascularization. At end of study Dastjerdi et al reported that a 47.1% decrease in mean neovascular area (p= 0.0014) and a 54.1% decrease in vessel caliber (p = 0.00009) was noted in all such patients. 12 Subconjunctival bevacizumab therapy in patients having corneal neovascularization shown good results. Like in a study of Chu et al that conducted study in 2011 on 18 patients with lipid keratopathy secondary to corneal neovascularization. All such patients were injected with injections of subconjunctival bevacizumab on monthly basis for three months. On follow up these patients Chu et al measured the extent, centricity, and percentage of involved corneal surface secondary to neovascularization. They observed that after treatment with bevacizumab all above mentioned parameters of corneal neovascularization and lipid deposition showed significant improvement (all p < 0.05). 13 Further human study conducted by YOU et al also demonstrate significant reduction in corneal neovascularization after treatment of patients with subconjunctivally injected bevacizumab. They further recommended that higher doses of bevacizumab (5.0 mg vs 2.5 mg) for getting better results in such patients. 14 
But
Subconjunctival administration of bevacizumab does have its own unique risks. So more studies are conducted for comparing the safety of the Subconjunctiva methods and intraocular administration of bevacizumab before any conclusions can be drawn.
Some studies have also conducted in such patients by using bevacizumab intraocularlly.They injected these patients either by intracameral or by intravitreal route. Finally these recent comparative studies shown that bevacizumab either in form of intravitreal, or intracameral is more effective as compared to subconjunctival administration for decreasing corneal neovascularization. Avisar et al conducted a study in experimental models by administrating bevacizumab intravitreal and anterior chamber injection .Finally they concluded that both routes also more excellent for decreasing new vessels in models for up to 10 days. However Mouse strains vary in their response to the administration of anti-VEGF agents most like due to their different genetic make up. 15 As well in models, s corneas with intact epithelium topically applied bevacizumab is not able to penetrate. 16 Therefore, these studies must be replicated in humans.
So, according to our study, the efficacy of subconjuctival injection of bevacizumab on patients having corneal neovascularization following keratoplasty is higher and can be used further in our population.
CONCLUSION
We concluded that the frequency of efficacy of subconjuctival bevacizumab is higher in patients having corneal neovascularization after corneal transplantation. So we recommended the use of subconjuctival bevacizumab to reduce the risk of corneal graft rejection following Keratoplasty by regressing the corneal neovascularization and making cornea transparent after Keratoplasty. 
